Welcome to our dedicated page for Harrow Health SEC filings (Ticker: HROW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Harrow, Inc. (HROW) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. Harrow is an ophthalmic-focused pharmaceutical company whose common stock trades on the Nasdaq Stock Market, and its filings offer detailed information about its financial condition, capital structure, and material corporate events.
Harrow’s current reports on Form 8-K include disclosures about quarterly financial results, investor presentations, credit agreements, leadership changes at subsidiaries, and business development transactions. For example, recent 8-K filings describe the announcement of financial results for the period ended September 30, 2025, the entry into and terms of a senior secured revolving credit facility with a commercial bank, and the agreement to acquire, and subsequent completion of the acquisition of, Melt Pharmaceuticals, Inc., a clinical-stage company developing non-opioid, non-IV sedation therapies.
The company’s filings also document capital markets and debt activities. Harrow has reported the pricing of senior unsecured notes due 2030 in a private offering and related plans to use the proceeds to repay existing debt and redeem previously issued senior notes. Separate Form 25 filings by the Nasdaq Stock Market LLC show the removal from listing and registration of Harrow’s 8.625% senior notes due 2026 and 11.875% senior notes due 2027.
Through Stock Titan, users can follow Harrow’s 10-K annual reports, 10-Q quarterly reports, and 8-K current reports as they are made available on EDGAR. AI-powered summaries help explain the key points in these documents, including revenue trends, operating results, debt arrangements, and the terms of material agreements such as merger agreements and credit facilities. The filings page also surfaces information relevant to equity and debt investors, including unregistered sales of equity securities disclosed in connection with milestone-based consideration for acquisitions.
For investors analyzing Harrow’s ophthalmic and procedural sedation strategy, the SEC filings provide primary-source detail on transaction structures, milestone obligations, and financial covenants. Stock Titan’s tools are designed to make these complex filings easier to review by highlighting important sections and presenting concise explanations of the underlying disclosures.
Harrow, Inc. reported that it has completed the acquisition of Melt Pharmaceuticals, Inc. on November 17, 2025 under a previously announced merger agreement. At closing, Harrow paid approximately
Harrow, Inc. (HROW) reported Q3 2025 results, showing strong top-line growth and a swing to profitability for the quarter while executing a major refinancing. Revenue rose to $71.6 million from $49.3 million a year ago, driven mainly by product sales of $71.5 million. Gross profit reached $53.9 million. Operating income was $14.7 million, and net income was $1.0 million (diluted EPS $0.03) versus a prior-year loss.
Year to date, Harrow recorded a net loss of $11.8 million, reflecting higher interest expense and a $7.8 million loss on extinguishment of debt tied to balance sheet changes. The company issued $250.0 million of 8.625% senior notes due 2030 and repaid its Oaktree Loan and 2026/2027 notes in September. Cash and cash equivalents were $74.3 million at quarter end, supported by $35.5 million net cash provided by operating activities for the first nine months of 2025. Shares outstanding were 37,037,453 as of November 10, 2025.
Harrow, Inc. (HROW) furnished materials announcing financial results for the period ended September 30, 2025 and recent corporate updates. The company provided a press release, a stockholder letter, and an investor presentation for reference.
These materials were furnished under Items 2.02 and 7.01 and are not deemed “filed” for liability purposes or incorporated by reference unless expressly stated. Exhibits include a press release, stockholder letter, and a corporate presentation.
Harrow, Inc. director/officer Francis William Mullery Jr. reported an initial beneficial ownership filing dated
Harrow, Inc. submitted a Form 25 notification concerning removal of its registered class of securities from the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934. The filing identifies the issuer's principal office in Nashville, Tennessee, and includes a contact telephone number. The document lists the standard regulatory rule checkboxes for striking a listing but does not indicate which specific rule provision was selected or provide an effective delisting date.
The filing states that Nasdaq certifies it has complied with exchange rules to strike the securities and that the issuer has complied with exchange requirements governing voluntary withdrawal, where applicable. Other than procedural certification and administrative details (including an OMB control number), the filing contains no financial results, transactions, or reasons for the removal.
Nasdaq Stock Market LLC has filed a Form 25 notification to remove the class of securities of Harrow, Inc. (HROW) from listing and/or registration on the Nasdaq exchange. The filing identifies the issuer and exchange and certifies Nasdaq believes it meets the requirements to submit this notice. The document does not include a signed signature block or detail which rule provision was checked for the removal.
Harrow, Inc. reported a leadership change at its wholly owned subsidiary ImprimisRx, LLC. On October 6, 2025, John Saharek ceased serving as President and Chief Executive Officer of ImprimisRx and certain affiliated entities, effective that date. He has moved into a non-officer leadership role at Harrow and will no longer be involved in ImprimisRx’s operations. The company did not enter into any new compensatory arrangements with him in connection with this transition.
Harrow also issued a press release on October 6, 2025, announcing these leadership changes at ImprimisRx, which is furnished as an exhibit and incorporated by reference.
Harrow, Inc. filed an amended current report to add full copies of key agreements for its planned acquisition of Melt Pharmaceuticals, Inc. as exhibits. The amendment attaches the Agreement and Plan of Merger dated September 24, 2025, among Harrow, its merger subsidiary, Melt, and D. Brad Osborne as stockholder representative, along with a related Milestone Payment Agreement between Harrow and Melt. The company states that no other changes are being made to the earlier report that first described the merger. Harrow also emphasizes that the representations, warranties and covenants in these agreements were made for the benefit of the parties as of specific dates and may use different materiality standards than investors, so they should not be read as full factual descriptions of the companies’ current condition.
Harrow, Inc. and certain subsidiaries entered into a new senior secured revolving credit agreement with Fifth Third Bank providing an initial facility of $40.0 million and an uncommitted incremental revolving line up to $20.0 million. The facility is secured and includes subsidiary guarantors, and it matures on September 26, 2030 or, if earlier, 91 days prior to the earliest maturity date of the company’s 8.625% senior notes due 2030. The credit line increases the company’s committed liquidity and provides flexibility through an additional uncommitted incremental option; the agreement names Fifth Third as administrative agent, letter of credit issuer, swing line lender, lead arranger and bookrunner.
Harrow, Inc. filed a current report to share materials from its Investor Day held on September 26, 2025. The company furnished an investor presentation as Exhibit 99.1, which was used at the event and in subsequent investor meetings. The information in the presentation and in this disclosure is furnished under Regulation FD and is expressly stated as not being deemed “filed” for purposes of Section 18 of the Exchange Act, nor automatically incorporated into other Securities Act or Exchange Act filings.